Fadi Haddad, Assistant Professor at The University of Texas MD Anderson Cancer Center, shared a post on X:
“The long awaited outcome of the VERONA trial is out.
Randomized Ph 3 trial
Aza + Ven versus Aza + placebo in newly diagnosed high-risk MDS
Primary endpoint of OS not met (HR 0.9)
What does this mean to the MDS and leukemia community?”
More posts featuring VERONA trial.